Assenagon Asset Management
TGTX icon

Assenagon Asset Management’s TG Therapeutics TGTX Stock Holding History

Assenagon Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Sell
91,681
-418,373
-82% -$17.1M 0.01% 663
2026
Q1 		$16.9M Buy
510,054
+349,664
+218% +$10.4M 0.03% 362
2025
Q4 		$4.78M Buy
160,390
+148,757
+1,279% +$4.86M 0.01% 650
2025
Q3 		$420K Buy
11,633
+5,461
+88% +$180K ﹤0.01% 1080
2025
Q2 		$222K Hold
6,172
– – ﹤0.01% 1114
2025
Q1 		$243K Sell
6,172
-96,908
-94% -$3.26M ﹤0.01% 1093
2024
Q4 		$3.1M Sell
103,080
-67,154
-39% -$1.93M 0.01% 817
2024
Q3 		$3.98M Sell
170,234
-318,709
-65% -$6.96M 0.01% 772
2024
Q2 		$8.7M Buy
+488,943
New +$7.8M 0.02% 470
2023
Q4 		– Sell
-145,846
Closed -$1.22M – 1488
2023
Q3 		$1.22M Buy
+145,846
New +$2.03M ﹤0.01% 997
2023
Q2 		– Sell
-230,602
Closed -$3.47M – 1463
2023
Q1 		$3.47M Buy
+230,602
New +$3.5M 0.01% 673
2022
Q3 		– Sell
-2,088,952
Closed -$8.88M – 1541
2022
Q2 		$8.88M Buy
2,088,952
+1,834,924
+722% +$11.5M 0.03% 397
2022
Q1 		$2.42M Buy
254,028
+92,349
+57% +$1.07M 0.01% 761
2021
Q4 		$3.07M Buy
+161,679
New +$4.2M 0.01% 673
2021
Q3 		– Sell
-152,823
Closed -$5.93M – 1429
2021
Q2 		$5.93M Sell
152,823
-3,424
-2% -$134K 0.02% 444
2021
Q1 		$7.53M Buy
+156,247
New +$7.51M 0.03% 404
2019
Q1 		– Sell
-156,700
Closed -$642K – 1114
2018
Q4 		$642K Buy
+156,700
New +$779K 0.01% 763

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Assenagon Asset Management's TGTX Position: Q2 2026 in Review

Assenagon Asset Management reduced its TG Therapeutics (TGTX) stake by 82% in Q2 2026, selling an estimated $17.1M and leaving 91,681 shares worth $5.04M. The position accounts for 0.01% of the portfolio, ranked #663.

Assenagon Asset Management first reported a position in TGTX in Q4 2018 and has held it in 17 quarters since. The position peaked at $16.9M in Q1 2026. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Assenagon Asset Management held 91,681 shares of TG Therapeutics worth $5.04M as of Q2 2026.
  • Assenagon Asset Management sold 418,373 TG Therapeutics shares in Q2 2026, an estimated $17.1M.
  • TG Therapeutics made up 0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #663 holding.
  • Assenagon Asset Management first reported a position in TG Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Assenagon Asset Management's TG Therapeutics position peaked at $16.9M in Q1 2026.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.